Cyberkinetics Neurotechnology Systems, Inc. (OTCBB: CYKN; Cyberkinetics), a neurotechnology company developing neurostimulation and neural sensing products designed to restore function, announced that it has been issued U.S. patent 7,199,110, entitled "Method of Treatment for Spinal Cord Injury, by the United States Patent and Trademark Office. The patent relates to the Company's Andara Oscillating Field Stimulator (OFS) Therapy neural stimulation technology platform.
"In February 2007, Cyberkinetics filed a Humanitarian Device Exemption to market the Andara OFS System to treat people with spinal cord injuries within 18 days following their injuries, stated Timothy R. Surgenor, Cyberkinetics' President and Chief Executive Officer. "This new patent covers the use of Cyberkinetics' Andara OFS System in combination with a growth factor, which may ultimately enable us to treat people with spinal cord and other nervous system injuries suffered months or years earlier.
The Company's current patent portfolio now includes five issued patents and more than 50 pending patent applications covering systems, methods, devices and compounds for nerve repair, as well as neural interface technologies for diagnostic, therapeutic and functional restoration products.
About Cyberkinetics Neurotechnology Systems, Inc.
Cyberkinetics Neurotechnology Systems, Inc., a leader in the neurotechnology industry, is developing neural stimulation, sensing and processing technology to improve the lives of those with severe paralysis resulting from spinal cord injuries, neurological disorders and other conditions of the nervous system. Cyberkinetics' product development pipeline includes: Andara OFS Therapy for acute spinal cord injury, an investigative device designed to stimulate nerve repair and restore sensation and motor function; the BrainGate System, an investigative device designed to provide communication and control of a computer, assistive devices, and, ultimately, limb movement; and a pilot program in the detection and prediction of seizures due to epilepsy. Additional information is available at Cyberkinetics' website at http://www.cyberkineticsinc.com.
Forward-Looking Statements
This announcement contains forward-looking statements, including statements about Cyberkinetics' product development plans and progress, potential development of proprietary inventions and benefits that may be realized by certain research programs. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and can be identified by the use of forward-looking terminology such as "may," "will," "believe," "expect," "anticipate" or other comparable terminology. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected in forward-looking statements and reported results shall not be considered an indication of our future performance. Factors that might cause or contribute to such differences include our limited operating history; our lack of profits from operations; our ability to successfully develop and commercialize our proposed products; a lengthy approval process and the uncertainty of FDA and other governmental regulatory requirements; clinical trials may fail to demonstrate the safety and effectiveness of our products; the degree and nature of our competition; our ability to employ and retain qualified employees; compliance with recent legislation regarding corporate governance, including the Sarbanes-Oxley Act of 2002; as well as those risks more fully discussed in our public filings with the Securities and Exchange Commission, all of which are difficult to predict and some of which are beyond our control.
